Insmed, Inc. $INSM Shares Purchased by Atria Investments Inc

Atria Investments Inc boosted its position in Insmed, Inc. (NASDAQ:INSM) by 75.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,810 shares of the biopharmaceutical company’s stock after purchasing an additional 7,219 shares during the quarter. Atria Investments Inc’s holdings in Insmed were worth $1,692,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in INSM. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Insmed in the 1st quarter worth $975,000. Chung Wu Investment Group LLC acquired a new stake in shares of Insmed in the 2nd quarter worth $173,000. OneDigital Investment Advisors LLC increased its position in shares of Insmed by 47.1% during the 1st quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company’s stock worth $399,000 after purchasing an additional 1,673 shares during the last quarter. Caxton Associates LLP acquired a new stake in shares of Insmed during the 1st quarter worth about $441,000. Finally, Assenagon Asset Management S.A. increased its position in shares of Insmed by 84.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock worth $7,387,000 after purchasing an additional 33,626 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on INSM shares. UBS Group raised their price objective on Insmed from $194.00 to $223.00 and gave the stock a “buy” rating in a research report on Friday. Bank of America boosted their price objective on Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Jefferies Financial Group raised their price objective on shares of Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, August 13th. The Goldman Sachs Group lifted their price objective on shares of Insmed from $196.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Royal Bank Of Canada increased their target price on Insmed from $139.00 to $215.00 and gave the company an “outperform” rating in a report on Friday. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $173.29.

Insider Activity

In related news, insider Michael Alexander Smith sold 24,272 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total transaction of $3,492,498.08. Following the completion of the sale, the insider owned 54,902 shares in the company, valued at $7,899,848.78. The trade was a 30.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 6,865 shares of Insmed stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $128.40, for a total value of $881,466.00. Following the transaction, the chief executive officer directly owned 233,924 shares in the company, valued at approximately $30,035,841.60. This trade represents a 2.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 152,657 shares of company stock valued at $21,442,198 over the last 90 days. Insiders own 3.00% of the company’s stock.

Insmed Price Performance

INSM stock opened at $182.77 on Wednesday. The business has a 50 day moving average price of $154.19 and a 200 day moving average price of $114.25. The stock has a market cap of $38.63 billion, a price-to-earnings ratio of -32.01 and a beta of 1.03. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $197.08. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The business had revenue of $142.34 million for the quarter, compared to analysts’ expectations of $114.33 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.Insmed’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.27) EPS. Insmed has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.